On Dec. 17, 2020, Regeneron announced that the New England Journal of Medicine (NEJM) had published initial clinical data from an ongoing seamless Phase 1/2/3 trial of the antibody cocktail casirivimab and imdevimab in non-hospitalized patients with COVID-19.